SCHEMBL6943777

SCHEMBL6943777

CC(NC(=O)c1cc([N+](=O)[O-])ccc1NC1CCC(O)CC1)c1ccccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
KMT2A Q03164 4/20 0.45
RORC P51449 1/20 0.43
TRPA1 O75762 1/20 0.40
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
SLC6A9 P48067 2/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
CASP3 P42574 1/20 0.38
CASP7 P55210 1/20 0.38
HSP90AA1 P07900 1/20 0.38
SLC6A5 Q9Y345 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.36
PDE3B Q13370 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944000 0.84 MAPT (0.57) MAPTKMT2ALMNAMEN1ALDH1A1
SCHEMBL6944003 0.84 MAPT (0.57) MAPTKMT2ALMNAMEN1ALDH1A1
SCHEMBL6943782 0.79 MAPT (0.49) MAPTKMT2ARORCLMNAMEN1
SCHEMBL6943780 0.79 MAPT (0.49) MAPTKMT2ARORCLMNAMEN1
SCHEMBL6941586 0.73 MAPT (0.58) MAPTKMT2ATRPA1LMNAMEN1
SCHEMBL6941409 0.73 MAPT (0.58) MAPTKMT2ATRPA1LMNAMEN1
SCHEMBL6941411 0.73 MAPT (0.58) MAPTKMT2ATRPA1LMNAMEN1
SCHEMBL6937260 0.73 MAPT (0.59) MAPTKMT2ATRPA1LMNAMEN1
SCHEMBL6937256 0.73 MAPT (0.59) MAPTKMT2ATRPA1LMNAMEN1
SCHEMBL6940663 0.72 MAPT (0.52) MAPTKMT2ALMNAALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1080069-B1 ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE FUJISAWA PHARMACEUTICAL CO (JP) 2003-03-19 EP disclosed
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-12-19 US disclosed
US-6384080-B1 TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-07 US disclosed
CN-1305454-A Anthranilic acid derivatives as inhibitors of CGMP phosphodiesterase FUJISAWA PHARMACEUTICAL CO (JP) 2001-07-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193614-A1 Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase PDE3A, PDE2A, PDE5A MAPT 4706/4885KMT2A 1991/4885RORC 2533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.